Thermo-responsive polymeric nanoparticles for enhancing neuronal differentiation of human induced pluripotent stem cells

Seo, Hogyun; Cho, Ann Na; Jang, Jiho; Kim, Dong Wook; Cho, Seung Woo; Chung, Bong Geun

doi:10.1016/j.nano.2015.05.008

Cited by 40 publications

(25 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possibility of using the NWs as MRI contrast agents opens the door for theranostics in diseases such as cancer, where different strategies can be combined for targeting (magnetic guiding and targeting agents) and for treatment, while following the process in a non-invasive manner. Specifically, MRI cell tracking with NWs can be applied for cell therapy in diverse pathologies including degenerative disorders, where pluripotent cells labeled with NWs can be magnetically guided and concentrated into the target site and their differentiation induced by photothermal, magnetic or mechanical responses of the NWs, as suggested in different publications [77][78][79][80].…”

Section: Magnetic Resonance Imaging Of Nanowires Internalized In Breamentioning

confidence: 99%

Magnetic core–shell nanowires as MRI contrast agents for cell tracking

et al. 2020

View full text Add to dashboard Cite

Background: Identifying the precise location of cells and their migration dynamics is of utmost importance for achieving the therapeutic potential of cells after implantation into a host. Magnetic resonance imaging is a suitable, non-invasive technique for cell monitoring when used in combination with contrast agents. Results: This work shows that nanowires with an iron core and an iron oxide shell are excellent materials for this application, due to their customizable magnetic properties and biocompatibility. The longitudinal and transverse magnetic relaxivities of the core-shell nanowires were evaluated at 1.5 T, revealing a high performance as T 2 contrast agents. Different levels of oxidation and various surface coatings were tested at 7 T. Their effects on the T 2 contrast were reflected in the tailored transverse relaxivities. Finally, the detection of nanowire-labeled breast cancer cells was demonstrated in T 2-weighted images of cells implanted in both, in vitro in tissue-mimicking phantoms and in vivo in mouse brain. Labeling the cells with a nanowire concentration of 0.8 μg of Fe/mL allowed the detection of 25 cells/µL in vitro, diminishing the possibility of side effects. This performance enabled an efficient labelling for high-resolution cell detection after in vivo implantation (~ 10 nanowire-labeled cells) over a minimum of 40 days. Conclusions: Iron-iron oxide core-shell nanowires enabled the efficient and longitudinal cellular detection through magnetic resonance imaging acting as T 2 contrast agents. Combined with the possibility of magnetic guidance as well as triggering of cellular responses, for instance by the recently discovered strong photothermal response, opens the door to new horizons in cell therapy and make iron-iron oxide core-shell nanowires a promising theranostic platform.

show abstract

Section: Magnetic Resonance Imaging Of Nanowires Internalized In Breamentioning

confidence: 99%

Magnetic core–shell nanowires as MRI contrast agents for cell tracking

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In particular, astrocyte‐derived RA protects BBB integrity by decreasing immune cell adhesion to the endothelium while reducing oxidative stress and endothelial activation (Mizee et al, ). Similarly, an ideal vehicle should allow controlled drug release for a long period of time, to mimic this cellular‐based process; this has been achieved with polymeric nanoparticles that were successfully internalized by neural and embryonic stem cells, promoting their differentiation by intracellularly releasing RA (Ku et al, ; Maia et al, ; Santos et al, ; Seo et al, ).…”

Section: Nanomedicine‐based Strategies For Strokementioning

confidence: 99%

Challenging the great vascular wall: Can we envision a simple yet comprehensive therapy for stroke?

Machado-Pereira

Santos

Ferreira

et al. 2017

J Tissue Eng Regen Med

View full text Add to dashboard Cite

Stroke is a leading cause of death in adult life, closely behind ischemic heart disease, and causes a significant and abiding socioeconomic burden. However, current therapies are not able to ensure full neurologic and/or sequelae-free recovery to all stroke survivors. We believe treatment efficacy and patient rehabilitation could be enhanced significantly by targeting bloodbrain barrier (BBB) deregulation and inflammation-induced barrier loss that occurs after stroke. In this pathological context, bone marrow-derived endothelial progenitor cells (EPC) enter the bloodstream towards the lesion site, but their insufficient numbers and impaired angiogenic ability compromise neurovascular regeneration. In this context, cell-based therapies have become increasingly appealing since treating patients with large numbers of mesenchymal or hematopoietic stem/progenitor cells alone may boost repair. However, this approach could be met with several challenges in terms of logistics and cost; hence, the development of a drug delivery system suitable for intravenous administration and functionalized for selective uptake by circulating EPC could enhance their restorative potential without perceived complications. The ability to encapsulate proangiogenic and anti-inflammatory agents, such as retinoic acid, and to safely and easily deliver them systemically may open new therapeutic perspectives for the treatment of cerebrovascular disorders.

show abstract

“…There is growing applications in nanoparticle and synthetic carriers as reprogramming systems for generation of iPSCs. For instance, after retinoic acid (RA) was efficiently incorporated into poly(N-isopropylacrylamide)-co-acrylamide nanoparticles, this nanoparticle could be a potentially powerful carrier for effective RA delivery to direct human iPSC fate to the neuronal lineage [97]. Tavernier et al generated mouse iPSCs from MEFs using a different cationic lipid carrier fused with OSKM mRNAs [98].…”

Section: Synthetic Carriersmentioning

confidence: 99%

Current Reprogramming Systems in Regenerative Medicine: From Somatic Cells to Induced Pluripotent Stem Cells

2015

Regen. Med.

View full text Add to dashboard Cite

Induced pluripotent stem cells (iPSCs) paved the way for research fields including cell therapy, drug screening, disease modeling and the mechanism of embryonic development. Although iPSC technology has been improved by various delivery systems, direct transduction and small molecule regulation, low reprogramming efficiency and genomic modification steps still inhibit its clinical use. Improvements in current vectors and the exploration of novel vectors are required to balance efficiency and genomic modification for reprogramming. Herein, we set out a comprehensive analysis of current reprogramming systems for the generation of iPSCs from somatic cells. By clarifying advantages and disadvantages of the current reprogramming systems, we are striding toward an effective route to generate clinical grade iPSCs.

show abstract

Thermo-responsive polymeric nanoparticles for enhancing neuronal differentiation of human induced pluripotent stem cells

Cited by 40 publications

References 56 publications

Magnetic core–shell nanowires as MRI contrast agents for cell tracking

Magnetic core–shell nanowires as MRI contrast agents for cell tracking

Challenging the great vascular wall: Can we envision a simple yet comprehensive therapy for stroke?

Current Reprogramming Systems in Regenerative Medicine: From Somatic Cells to Induced Pluripotent Stem Cells

Contact Info

Product

Resources

About